Medicare’s coverage and payment policies for new COVID-19 antibody drugs are subject to change and may depend on various factors such as FDA approval, clinical trial data, and the specific drug’s labeling.
As of my knowledge cutoff date, Medicare had established a national coverage policy for monoclonal antibody treatments for COVID-19, including bamlanivimab and etesevimab administered together and casirivimab and imdevimab administered together. Medicare has agreed to cover these treatments when they are administered to patients who meet specific criteria, including a positive COVID-19 test and high risk for severe illness or hospitalization.
The coverage of new COVID-19 antibody drugs may follow similar criteria, and it is advisable to check with Medicare or your healthcare provider for the latest information on coverage and payment policies.